Primary membranous nephropathy: an endless story

[1]  Wen-Ting Yan,et al.  Efficacy and Safety of Different Immunosuppressive Therapies in Patients With Membranous Nephropathy and High PLA2R Antibody Titer , 2022, Frontiers in Pharmacology.

[2]  Ming-hui Zhao,et al.  Effects of hydroxychloroquine on proteinuria in membranous nephropathy , 2021, Journal of Nephrology.

[3]  X. Geiger,et al.  Malignancy-Associated Membranous Nephropathy with Positive Anti-PLA2R Autoantibodies: Coincidence or Connection , 2021, Case Reports in Nephrology and Dialysis.

[4]  Ashwani Kumar,et al.  Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function , 2021, Nephron.

[5]  B. Rovin,et al.  Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[6]  N. Bec,et al.  Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. , 2021, Kidney international.

[7]  S. Faguer,et al.  Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy. , 2021, Kidney international.

[8]  B. Rovin,et al.  Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy , 2021, Kidney international reports.

[9]  Aaron J. Storey,et al.  Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy , 2021, Journal of the American Society of Nephrology : JASN.

[10]  L. Gesualdo,et al.  Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. , 2021, Journal of the American Society of Nephrology : JASN.

[11]  K. Uchiyama,et al.  Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma , 2021, CEN Case Reports.

[12]  Y. Caliskan,et al.  Clinical significance of glomerular C3 deposition in primary membranous nephropathy , 2021, Journal of Nephrology.

[13]  S. Sethi.  New 'Antigens' in Membranous Nephropathy. , 2020, Journal of the American Society of Nephrology : JASN.

[14]  D. Salant,et al.  Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1 associated membranous nephropathy. , 2020, The Journal of clinical investigation.

[15]  C. Ponticelli,et al.  Secondary Membranous Nephropathy. A Narrative Review , 2020, Frontiers in Medicine.

[16]  J. Wetzels,et al.  The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. , 2020, Kidney international.

[17]  S. Jordan,et al.  Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy , 2020, Kidney international reports.

[18]  F. Fervenza,et al.  Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  L. Kiemeney,et al.  The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis , 2020, Nature Communications.

[20]  G. Remuzzi,et al.  Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness , 2020, BMJ Case Reports.

[21]  K. Dahan,et al.  Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD , 2019, Kidney international reports.

[22]  G. Zahner,et al.  Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy. , 2019, Journal of the American Society of Nephrology : JASN.

[23]  V. D’Agati,et al.  Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[24]  K. Dahan,et al.  High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[25]  G. Remuzzi,et al.  Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab , 2019, Nephron.

[26]  B. Rovin,et al.  Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. , 2019, The New England journal of medicine.

[27]  R. B. Henderson,et al.  Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  E. Imai,et al.  Immunology of membranous nephropathy , 2019, F1000Research.

[29]  D. Salant.  Unmet challenges in membranous nephropathy , 2019, Current opinion in nephrology and hypertension.

[30]  A. Köttgen,et al.  Genetics of membranous nephropathy , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  E. Kamyshova,et al.  Genetic determinants of the development and course of membranous nephropathy. , 2018, Terapevticheskii arkhiv.

[32]  V. Jha,et al.  PLA2R related primary membranous nephropathy in a hepatitis C positive patient , 2018, Nephrology.

[33]  T. Yoo,et al.  The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial , 2018, Journal of Korean medical science.

[34]  Ming-hui Zhao,et al.  Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  K. Dahan,et al.  Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[36]  A. Dinda,et al.  Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience , 2017, Clinical kidney journal.

[37]  Ming-hui Zhao,et al.  Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[38]  L. Beck.  PLA2R and THSD7A: Disparate Paths to the Same Disease? , 2017, Journal of the American Society of Nephrology : JASN.

[39]  Zhi-Hong Liu,et al.  HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[40]  A. Barbari,et al.  Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy. , 2017, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[41]  K. Nath,et al.  A Proposal for a Serology-Based Approach to Membranous Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[42]  L. Del Vecchio,et al.  Low-dose rituximab is poorly effective in patients with primary membranous nephropathy , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  K. Dahan,et al.  Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. , 2017, Journal of the American Society of Nephrology : JASN.

[44]  H. Anders,et al.  Glomerular disease: Membranous nephropathy and the Henle–Koch postulates , 2016, Nature Reviews Nephrology.

[45]  K. Budde,et al.  Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. , 2016, The Journal of clinical investigation.

[46]  J. Balow,et al.  Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab , 2016, Kidney international reports.

[47]  S. Baldovino,et al.  New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. , 2016, Autoimmunity reviews.

[48]  W. Cheungpasitporn,et al.  Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis , 2016, Clinical kidney journal.

[49]  G. Lambeau,et al.  Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. , 2016, Journal of the American Society of Nephrology : JASN.

[50]  S. Brodsky,et al.  IgG Subclass Staining in Routine Renal Biopsy Material , 2016, The American journal of surgical pathology.

[51]  J. Wetzels,et al.  Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study , 2015, PloS one.

[52]  G. Remuzzi,et al.  Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy , 2015, PloS one.

[53]  Xiaoye Zhu,et al.  Renal Phospholipase A2 Receptor in Hepatitis B Virus-Associated Membranous Nephropathy , 2015, American Journal of Nephrology.

[54]  H. Debiec,et al.  Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[55]  I. Ben-Aharon,et al.  Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma? , 2015, Human reproduction.

[56]  A. Shimizu,et al.  Glomerular Endothelial Cell Injury and Focal Segmental Glomerulosclerosis Lesion in Idiopathic Membranous Nephropathy , 2015, PLoS ONE.

[57]  G. Remuzzi,et al.  Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[58]  R. Glassock,et al.  Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[59]  T. Jowitt,et al.  Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[60]  F. Akhtar,et al.  Rituximab as a rescue therapy in patients with glomerulonephritis. , 2015, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[61]  J. Klein,et al.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. , 2015, The New England journal of medicine.

[62]  M. Beggs,et al.  PLA2R-associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes , 2014, Genes and Immunity.

[63]  D. Cattran,et al.  A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[64]  C. Ponticelli,et al.  Glomerular diseases: membranous nephropathy--a modern view. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[65]  Xiangmei Chen,et al.  Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function , 2014, JN. Journal of Nephrology (Milano. 1992).

[66]  T. Muthukumar,et al.  Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy , 2014, Journal of Nephrology.

[67]  C. Ponticelli,et al.  Treatment of membranous nephropathy in patients with renal insufficiency: what regimen to choose? , 2013, JN. Journal of Nephrology (Milano. 1992).

[68]  D. Adu,et al.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial , 2013, The Lancet.

[69]  U. Panzer,et al.  Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. , 2012, Kidney international.

[70]  J. Wetzels,et al.  Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[71]  G. Remuzzi,et al.  Rituximab in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[72]  K. Dahan,et al.  Rituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients , 2011, Nephron Extra.

[73]  David M. Beck,et al.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[74]  L. Kiemeney,et al.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. , 2011, The New England journal of medicine.

[75]  A. Cybulsky.  Membranous nephropathy. , 2011, Contributions to nephrology.

[76]  F. Cosio,et al.  Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[77]  克治 桑門.  海外論文紹介 : M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy , 2010 .

[78]  M. Nogier,et al.  Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[79]  A. Loft,et al.  Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. , 2008, The Journal of rheumatology.

[80]  M. Vervloet,et al.  Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[81]  K. Sud,et al.  A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.

[82]  J. Luño,et al.  Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. , 2007, Kidney international.

[83]  M. Nangaku,et al.  Cellular and molecular biology of membranous nephropathy. , 2006, Journal of nephrology.

[84]  B. Stengel,et al.  Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. , 2006, Kidney international.

[85]  M. Salvadori,et al.  A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[86]  H. Debiec,et al.  Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. , 2005, Journal of the American Society of Nephrology : JASN.

[87]  J. Scholey,et al.  Idiopathic membranous nephropathy: definition and relevance of a partial remission. , 2004, Kidney international.

[88]  A. Komatsuda,et al.  Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[89]  C. Ponticelli,et al.  Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. , 2003, Seminars in nephrology.

[90]  J. Haymann,et al.  Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. , 2002, The New England journal of medicine.

[91]  D. Cattran.  Membranous nephropathy: quo vadis? , 2002, Kidney international.

[92]  J. Ehrich,et al.  A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children , 2001, Pediatric Nephrology.

[93]  P. Nilsson-ehle,et al.  Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. , 1999, Kidney international.

[94]  A. Lupo,et al.  A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. , 1998, Journal of the American Society of Nephrology : JASN.

[95]  C. Ponticelli,et al.  Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. , 1997, Kidney international.

[96]  J. Egido.  Renal diseases. , 2020, Clinical science.

[97]  C. Ponticelli,et al.  Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. , 1992, The New England journal of medicine.

[98]  F. Locatelli,et al.  Remissions and relapses in idiopathic membranous nephropathy. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[99]  F. Locatelli,et al.  A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. , 1989, The New England journal of medicine.

[100]  K. Konishi,et al.  Idiopathic membranous glomerulonephritis: aspects of geographical differences. , 1986, Journal of clinical pathology.

[101]  C. Ponticelli,et al.  A Randomized Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy , 1984 .

[102]  G. Neild,et al.  The long-term outcome of idiopathic membranous nephropathy. , 1981, Clinical nephrology.